Sign in to view content

ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330 a New Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su, MD

Video
Published 2023

Related

Staring a Clinical Trials Program
David A. Eichenbaum, MD, FASRS
Updates from the Field
2019
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
Types of Strokes Seen in Patients
Sophie Jane Bakri, MD
Updates from the Field
2017

Category: Diabetic Retinopathy

See more